In Vivo Efficacy and Safety Evaluations of Therapeutic Splicing Correction Using U1 snRNA in the Mouse Retina
Efficacy and safety considerations constitute essential steps during development of in vivo gene therapies. Herein, we evaluated efficacy and safety of splice factor-based treatments to correct mutation-induced splice defects in an <i>Opa1</i> mutant mouse line. We applied adeno-associat...
Main Authors: | Sebastian Swirski, Oliver May, Malte Ahlers, Bernd Wissinger, Martin Greschner, Christoph Jüschke, John Neidhardt |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-03-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/12/6/955 |
Similar Items
-
Autosomal dominant optic atrophy: A novel treatment for OPA1 splice defects using U1 snRNA adaption
by: Christoph Jüschke, et al.
Published: (2021-12-01) -
Minor introns are embedded molecular switches regulated by highly unstable U6atac snRNA
by: Ihab Younis, et al.
Published: (2013-07-01) -
The Cellular Processing Capacity Limits the Amounts of Chimeric U7 snRNA Available for Antisense Delivery
by: Agathe Eckenfelder, et al.
Published: (2012-01-01) -
An Exon-Specific U1snRNA Induces a Robust Factor IX Activity in Mice Expressing Multiple Human FIX Splicing Mutants
by: Dario Balestra, et al.
Published: (2016-01-01) -
A nuclear function for an oncogenic microRNA as a modulator of snRNA and splicing
by: Rachid El Fatimy, et al.
Published: (2022-01-01)